Clinical trial · Observational
The Effects of Circadian Gene on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy
The Effects of Per3, Clock Polymorphism on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy.
NCT01887925CI-TRIAL-00019970completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is the evaluation of effect of circadian gene on sleep and other symptoms in breast cancer patients under chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- breast cancer
- description
- breast cancer patients receiving chemotherapy
Primary outcomes (1)
- measure
- Changes from Baseline Sleep Impairment at 1 Month After Chemotherapy
- timeFrame
- baseline, 1 month, 3 months, 1 month after chemotherpy completion
- description
- Sleep impairment will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy.
Secondary outcomes (7)
- measure
- Changes from Baseline Quality of Life at 1 Month After Chemotherapy
- timeFrame
- baseline, 1 month after chemotherpy completion
- description
- Quality of life will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month after completion of the chemotherapy.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 18-70 * Patient with breast cancer without metastasis * Patient received cancer surgery and medically stable * Patient will undergo chemotherapy for the first time in life * Patient have signed on the informed consent, and well understood the objective and procedure of this study Exclusion Criteria: * Patient received chemotherapy or radiotherapy * Patient had another cancer before * Patient have metastasis * Patient with severe medical condition * Patient had taken psychiatric medication more than 1 month in life * Patient worked the night shift for more than 1 month in 6 months
References
Publications (1)
- DERIVEDSon KL, Jung D, Lee KM, Yeom CW, Oh GH, Kim TY, Im SA, Lee KH, Spiegel D, Hahm BJ. Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer. J Korean Med Sci. 2022 Feb 7;37(5):e34. doi: 10.3346/jkms.2022.37.e34. PMID 35132840